Show simple item record

dc.contributor.authorShawa, IT
dc.contributor.authorFelmlee, Daniel
dc.contributor.authorHegazy, D
dc.contributor.authorSheridan, David
dc.contributor.authorCramp, Matthew
dc.date.accessioned2017-06-29T15:46:29Z
dc.date.issued2017-05-30
dc.identifier.issn1352-0504
dc.identifier.issn1365-2893
dc.identifier.urihttp://hdl.handle.net/10026.1/9568
dc.description.abstract

A rare outcome following exposure to hepatitis C virus (HCV) is a lack of observable infection as clinically measured by HCV RNA- or HCV-recognizing antibodies. The population who exhibit this trait is termed exposed uninfected (EU). Increasing evidence has refined characterization of these individuals, distinct from those who become infected but spontaneously clear HCV. Study of the EU population is highly pertinent for the discovery of antiviral mechanisms of resistance that can reveal antiviral therapeutic strategies. This review provides an overview of similarities and differences of the EU population relative to spontaneous resolvers and the majority whom develop chronic HCV infection, and focusses on possible mechanisms of resistance including innate and adaptive immunity, genetics and lipid interactions.

dc.format.extent1082-1088
dc.format.mediumPrint-Electronic
dc.languageen
dc.language.isoen
dc.publisherWiley
dc.subjectcytokines
dc.subjectexposed uninfected
dc.subjecthepatitis C virus
dc.subjectimmune response
dc.subjectliver
dc.subjectpeople who inject drugs
dc.subjectresistance
dc.titleExploration of potential mechanisms of HCV resistance in exposed uninfected intravenous drug users
dc.typejournal-article
dc.typeJournal Article
dc.typeReview
plymouth.author-urlhttps://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000416320500001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=11bb513d99f797142bcfeffcc58ea008
plymouth.issue12
plymouth.volume24
plymouth.publication-statusPublished online
plymouth.journalJournal of Viral Hepatitis
dc.identifier.doi10.1111/jvh.12720
plymouth.organisational-group/Plymouth
plymouth.organisational-group/Plymouth/Faculty of Health
plymouth.organisational-group/Plymouth/Faculty of Health/Peninsula Medical School
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA/UoA01 Clinical Medicine
plymouth.organisational-group/Plymouth/Research Groups
plymouth.organisational-group/Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED)
plymouth.organisational-group/Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED)/CBR
plymouth.organisational-group/Plymouth/Users by role
plymouth.organisational-group/Plymouth/Users by role/Academics
dc.publisher.placeEngland
dcterms.dateAccepted2017-03-27
dc.rights.embargodate2018-5-30
dc.identifier.eissn1365-2893
dc.rights.embargoperiodNot known
rioxxterms.versionofrecord10.1111/jvh.12720
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2017-05-30
rioxxterms.typeJournal Article/Review


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record


All items in PEARL are protected by copyright law.
Author manuscripts deposited to comply with open access mandates are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.
Theme by 
Atmire NV